Roche’s divarasib (KRAS G12C inhibitor) outperforms sotorasib and adagrasib in head-to-head study｜Taro Watanabe – note Posted on 2026年7月4日 by "難病" - Google News Roche's divarasib (KRAS G12C inhibitor) outperforms sotorasib and adagrasib in head-to-head study｜Taro Watanabe note
